{"filing":{"accession_number":"0001193125-26-263722","cik":"0001660334","ticker":"VRCA","company_name":"Verrica Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"d139416d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/d139416d8k.htm"},"events":[{"id":4363,"run_id":3814,"accession_number":"0001193125-26-263722","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Verrica Pharmaceuticals held an Annual Meeting of Stockholders with four proposals: election of directors, advisory approval of named executive officer compensation, ratification of KPMG LLP as auditor, and approval of the Amended and Restated 2018 Equity Incentive Plan. Vote results for all four proposals are disclosed with detailed tallies.","company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","filing_date":"2026-06-09","items":[{"id":5490,"accession_number":"0001193125-26-263722","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the Amended and Restated 2018 Equity Incentive Plan, which is a compensatory arrangement affecting directors and officers. The filing explicitly references the Plan's material terms and incorporates the proxy statement summary by reference, indicating this is a material equity compensation plan amendment requiring 8-K disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:14.543635+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5491,"accession_number":"0001193125-26-263722","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from an Annual Meeting covering four proposals: election of directors (Proposal 1), advisory approval of named executive officer compensation (Proposal 2), ratification of auditor KPMG LLP (Proposal 3), and approval of the Amended and Restated 2018 Equity Incentive Plan (Proposal 4). The filing presents vote tallies for each proposal with votes for, against, abstained, and broker non-votes, which is the standard format for Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:14.543635+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5490,"accession_number":"0001193125-26-263722","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the Amended and Restated 2018 Equity Incentive Plan, which is a compensatory arrangement affecting directors and officers. The filing explicitly references the Plan's material terms and incorporates the proxy statement summary by reference, indicating this is a material equity compensation plan amendment requiring 8-K disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:14.543635+00:00","company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","filing_date":"2026-06-09"},{"id":5491,"accession_number":"0001193125-26-263722","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from an Annual Meeting covering four proposals: election of directors (Proposal 1), advisory approval of named executive officer compensation (Proposal 2), ratification of auditor KPMG LLP (Proposal 3), and approval of the Amended and Restated 2018 Equity Incentive Plan (Proposal 4). The filing presents vote tallies for each proposal with votes for, against, abstained, and broker non-votes, which is the standard format for Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:14.543635+00:00","company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","filing_date":"2026-06-09"}]}